NCT05318755

China Gender-affirming Hormone Therapy Study

China Gender-affirming Hormone Therapy Study in Transgender Men and Women

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 240 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.

Detailed description

CGAHT will be conducted in one of the main transgender medical centers in Chinese mainland. Participants who are seeking for the start of GAHT will be enrolled from clinical visitors. Before GAHT, participants will be interviewed with questionaries about their life experience, gender identity and social economic conditions. Evaluations on mental and physical health will be performed at baseline and during the GAHT. Participants will be followed up to 12 months. GAHT will be given to transgender people according to the protocol recommended by the international guideline (doi: 10.1210/jc.2017-01658) .

Conditions

• Transgender
• Gender Incongruence

Interventions

Type	Name	Description
DRUG	GAHT for transgender men	Testosterone undecanoate
DRUG	GAHT for transgender women	Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)

Timeline

• Start date: 2022-04-16
• Primary completion: 2027-12-31
• Completion: 2028-12-31
• First posted: 2022-04-08
• Last updated: 2024-11-07

Locations

1 site across 1 country: China